Drugs / fluticasone/formoterol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00563056 | Sep 2007 → Apr 2008 | asthma | Mundipharma Research Limited | Completed | Met primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-04-18 | Mundipharma Research Limited | Mundipharma and Vectura announce plans to reformulate flutiform® (fluticasone propionate/formoterol fumarate) pressurised metered- dose inhaler (pMDI) as a commitment to reducing the product’s carbon footprint mundipharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fluticasone/formoterol | “The potent inhaled corticosteroid, fluticasone propionate (fluticasone), and the long-acting β2-agonist with a rapid onset of action, formoterol fumarate (formoterol), have now...” PMID 23368897 ↗ Feb 2013 |
| Known as | flutiform | “The potent inhaled corticosteroid, fluticasone propionate (fluticasone), and the long-acting β2-agonist with a rapid onset of action, formoterol fumarate (formoterol), have now...” PMID 23368897 ↗ Feb 2013 |
| Route | Inhaled | “single aerosol inhaler” PMID 23368897 ↗ Feb 2013 |